Cargando…

CD4-Targeted T Cells Rapidly Induce Remissions in Mice with T Cell Lymphoma

OBJECTIVE: To explore the immune cell therapy for T cell lymphoma, we developed CD4-specific chimeric antigen receptor- (CAR-) engineered T cells (CD4CART), and the cytotoxic effects of CD4CART cells were determined in vitro and in vivo. METHODS: CD4CART cells were obtained by transduction of lentiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Jie, Chen, Guanghua, Lv, Hui, XU, Liangjing, LIU, Huiwen, Chen, Tianping, Qu, Lijun, Wang, Jian, Cheng, Lemei, Hu, Shaoyan, Wang, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019637/ https://www.ncbi.nlm.nih.gov/pubmed/33855074 http://dx.doi.org/10.1155/2021/6614784

Ejemplares similares

High expression of FLT3 is a risk factor in leukemia
por: Cheng, Jie, et al.
Publicado: (2018)

The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice
por: Zhao, Kai, et al.
Publicado: (2023)

Rapid Remission in Peripheral T-Cell Lymphoma of the Nasal Type by the Bortezomib plus CHOP Therapy
por: Xue, Li-Jun, et al.
Publicado: (2010)

Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
por: Hu, Yongxian, et al.
Publicado: (2018)

Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin
por: Kim, Hee Kyung, et al.
Publicado: (2015)

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
por: Yan, Lingzhi, et al.
Publicado: (2020)

Analysis of RAS gene mutations in adverse events during first induction chemotherapy in childhood acute lymphoblastic leukemia
por: Chen, Tianping, et al.
Publicado: (2023)

Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas
por: Field, Kenneth A, et al.
Publicado: (2008)

Spontaneous Remission of Diffuse Large B Cell Lymphoma in the Stomach and the Continuation of Remission for 10 Years
por: Sugiyama, Toshiro, et al.
Publicado: (2018)

Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report
por: Xu, Jingyan, et al.
Publicado: (2021)

Spontaneous remission of African lymphoma.
por: Burkitt, D. P., et al.
Publicado: (1967)

CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China
por: Feng, Yanfen, et al.
Publicado: (2017)

Unique Presentation of Leukemic Cutaneous CD3/TCR- Phenotype T-Cell Lymphoma with Complete Remission after Allogeneic Stem Cell Transplantation
por: Şanlı, Hatice, et al.
Publicado: (2017)

A double blinded, placebo-controlled pilot study to examine reduction of CD34 (+)/CD117 (+)/CD133 (+) lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma
por: Ito, Daisuke, et al.
Publicado: (2017)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

Plasma Factors for the Differentiation of Hodgkin’s Lymphoma and Diffused Large B Cell Lymphoma and for Monitoring Remission
por: Zeng, Qun, et al.
Publicado: (2019)

Dysfunctional endothelial progenitor cells in patients with Hodgkin’s lymphoma in complete remission
por: Wiessman, Maya, et al.
Publicado: (2018)

Spontaneous remission in diffuse large cell lymphoma: a case report
por: Snijder, J., et al.
Publicado: (2019)

Complete Endoscopic and Histopathological Remission of Mantle Cell Lymphoma of the Gastrointestinal Tract
por: Mohy-ud-din, Nabeeha, et al.
Publicado: (2019)

Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime
por: Zhang, Canjing, et al.
Publicado: (2022)

Clonal Structure of Rapid-Onset MDV-Driven CD4+ Lymphomas and Responding CD8+ T Cells
por: Mwangi, William N., et al.
Publicado: (2011)

Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy
por: Yang, Chunmei, et al.
Publicado: (2020)

T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission
por: Elreda, Lauren, et al.
Publicado: (2014)

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
por: Li, Chenggong, et al.
Publicado: (2023)

Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy
por: Wang, Kai, et al.
Publicado: (2020)

CD1d-restricted peripheral T cell lymphoma in mice and humans
por: Bachy, Emmanuel, et al.
Publicado: (2016)

Long-Term Remission of Diabetes in NOD Mice Is Induced by Nondepleting Anti-CD4 and Anti-CD8 Antibodies
por: Yi, Zuoan, et al.
Publicado: (2012)

Haploidentical γδ T Cells Induce Complete Remission in Chemorefractory B-cell Non-Hodgkin Lymphoma
por: Bold, Anna, et al.
Publicado: (2023)

COVID-19 induced follicular lymphoma remission
por: Baptista, Renata Lyrio, et al.
Publicado: (2022)

Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission
por: Zhou, Min, et al.
Publicado: (2020)

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma
por: Dai, Hai-ping, et al.
Publicado: (2022)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
por: Liu, Yanlong, et al.
Publicado: (2022)

CD40-Activated B Cell Cancer Vaccine Improves Second Clinical Remission and Survival in Privately Owned Dogs with Non-Hodgkin's Lymphoma
por: Sorenmo, Karin U., et al.
Publicado: (2011)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

CD5+ follicular lymphoma rapidly transformed to high-grade B-cell lymphoma with double-hit: from BCL2 to MYC disruption
por: Soler-Espejo, Eva, et al.
Publicado: (2023)

Synchronous brain and intravascular B‐cell lymphoma after remission of an adult hemophagocytic syndrome
por: Fonseca, Válter R., et al.
Publicado: (2016)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
por: Houot, Roch, et al.
Publicado: (2022)

Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient
por: Zou, Rui, et al.
Publicado: (2023)

Long‐term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine‐plus‐camrelizumab epi‐immunotherapy and treatment cessation
por: Wang, Chunmeng, et al.
Publicado: (2023)

CD8(+) T cell memory is sustained in mice by hepatic stellate cells
por: Chen, Yi‐Ting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qi3vn4sr2ol27s6if12q95nbb5